Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS: In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy. Crossover from the chemotherapy group to the pembrolizumab group was permitted in the event of disease progression. The primary end point, progression-free survival, was assessed by means of blinded, independent, central radiologic review. Secondary end points were overall survival, objective response rate, and safety. RESULTS: Median progression-free survival was 10.3 months (95% confidence interval [CI], 6.7 to not reached) in the pembrolizumab group versus 6.0 months (95% CI, 4.2 to 6.2) in the chemotherapy group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.37 to 0.68; P<0.001). The estimated rate of overall survival at 6 months was 80.2% in the pembrolizumab group versus 72.4% in the chemotherapy group (hazard ratio for death, 0.60; 95% CI, 0.41 to 0.89; P=0.005). The response rate was higher in the pembrolizumab group than in the chemotherapy group (44.8% vs. 27.8%), the median duration of response was longer (not reached [range, 1.9+ to 14.5+ months] vs. 6.3 months [range, 2.1+ to 12.6+]), and treatment-related adverse events of any grade were less frequent (occurring in 73.4% vs. 90.0% of patients), as were grade 3, 4, or 5 treatment-related adverse events (26.6% vs. 53.3%). CONCLUSIONS: In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. (Funded by Merck; KEYNOTE-024 ClinicalTrials.gov number, NCT02142738 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, ICIs are also associated with frequent and potentially organ- or life-threatening immune-related adverse events (irAEs), which generally mimic autoimmune or inflammatory conditions”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“indeed, up to 90% of patients treated with ipilimumab and up to 70% of those treated with PD-1/PD-L1 antibodies experience at least one irAE).3,4”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial trials on anti-PD-1 and anti-PD-L1 inhibitors reported a significant association between pre-treatment intratumoral PD-L1 expression and response to treatment in a variety of tumor types including melanoma and NSCLC”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Reck et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Research works printed but not linked: 1
- Xiao HQ, 2016, Onco Targets Ther, 9, 1471
Cited by
Items 801–900 of 1,054
Yin, X., Liao, H., Hong, Y., Lin, N., Li, S., Xiang, Y., & Ma, X. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.002 · Cited by 126
Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy
Wang, Y., Du, J., Gao, Z., Sun, H., Mei, M., Wang, Y., Ren, Y., & Zhou, X. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02084-y · Cited by 125
The next generation of immunotherapy: keeping lung cancer in check
Somasundaram, A., & Burns, T. F. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0456-5 · Cited by 123
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
Santarpía, M., Liguori, A., Karachaliou, N., González‐Cao, M., Daffinà, M. G., D’Aveni, A., Marabello, G., Altavilla, G., & Rosell, R. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s119644 · Cited by 124
Correlation between sex and efficacy of immune checkpoint inhibitors (PD‐1 and CTLA‐4 inhibitors)
Wu, Y., Ju, Q., Jia, K., Yu, J., Shi, H., Wu, H., & Jiang, M. (2018) · International Journal of Cancer · doi:10.1002/ijc.31301 · Cited by 115
Min Lee, C. K., Li, S., Tran, D. C., Zhu, G. A., Kim, J., Kwong, B. Y., & Chang, A. L. S. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.05.035 · Cited by 119
Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance
Leprieur, E. G., Costantini, A., Ding, V. W., & He, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092835 · Cited by 123
George, J., Bajaj, D., Sankaramangalam, K. P., Yoo, J. W., Joshi, N. S., Gettinger, S. N., Price, C. C., & Farrell, J. J. (2019) · Pancreatology · doi:10.1016/j.pan.2019.04.015 · Cited by 123
Tumor Mutation Burden—From Hopes to Doubts
Addeo, A., Banna, G. L., & Weiss, G. J. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0626 · Cited by 123
Tan, A. C., Lai, G. G. Y., Tan, G. S., Poon, S. Y., Doble, B., Lim, T. H., Aung, Z. W., Takano, A. M., Tan, W. L., Ang, M., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.11.022 · Cited by 124
The balancing act: Immunology of leishmaniosis
Toepp, A. J., & Petersen, C. A. (2020) · Research in Veterinary Science · doi:10.1016/j.rvsc.2020.02.004 · Cited by 123
Yoneshima, Y., Morita, S., Ando, M., Nakamura, A., Iwasawa, S., Yoshioka, H., Gotô, Y., Takeshita, M., Harada, T., Hirano, K., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.027 · Cited by 124
Barnestein, R., Galland, L., Kalfeist, L., Ghiringhelli, F., Ladoire, S., & Limagne, E. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2120676 · Cited by 124
Duttagupta, S., Messaoudene, M., Hunter, S., Desîlets, A., Jamal, R., Mihalcioiu, C. L. D., Belkaïd, W., Marcoux, N., Fidelle, M., Suissa, D., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04186-5 · Cited by 124
Tsao, M., Teuff, G. L., Shepherd, F. A., Landais, C., Hainaut, P. L., Filipits, M., Pirker, R., Chevalier, T. L., Graziano, S. L., Kratze, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx003 · Cited by 122
Liu, C., Xu, J., Zhou, Z., Jin, L.-L., Yu, X.-J., Xiao, G., Lin, J., Zhuang, S., Zhang, Y., & Zheng, L. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0144-4 · Cited by 124
Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Ahern, E. S., Smyth, M. J., Dougall, W. C., & Teng, M. W. L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0095-y · Cited by 123
Immune Checkpoint Inhibitors in Real‐World Treatment of Older Adults with Non–Small Cell Lung Cancer
Muchnik, E., Loh, K. P., Strawderman, M. S., Magnuson, A. M., Mohile, S. G., Estrah, V., & Maggiore, R. J. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15750 · Cited by 122
Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
Kennedy, L. C., Bhatia, S., Thompson, J. A., & Grivas, P. D. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7310 · Cited by 122
Brown, L. C., Tucker, M. D., Sedhom, R., Schwartz, E. B., Zhu, J., Kao, C., Labriola, M., Gupta, R. T., Marin, D., Wu, Y. S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001792 · Cited by 122
der Welle, C. M. C., Verschueren, M. V., Tonn, M., Peters, B. J. M., Schramel, F. M. N. H., Klungel, O. H., Groen, H. J. M., van de Garde, E. M. W., The Santeon NSCLC Study Group, Kastelijn, E. A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85696-3 · Cited by 122
Noncoding RNA s and immune checkpoints—clinical implications as cancer therapeutics
Smolle, M. A., Calin, H. N., Pichler, M., & Calin, G. A. (2017) · The FEBS Journal · doi:10.1111/febs.14030 · Cited by 113
Akiba, T., Morikawa, T., Odaka, M., Nakada, T., Kamiya, N., Yamashita, M., Yabe, M., Inagaki, T., Asano, H., Mori, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0483 · Cited by 124
Jiang, T., Shi, J., Dong, Z., Hou, L., Zhao, C., Li, X., Mao, B., Zhu, W., Guo, X., Zhang, H., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0762-1 · Cited by 121
Pregnancy and Breast Cancer: Pathways to Understand Risk and Prevention
Slepicka, P. F., Cyrill, S. L., & dos Santos, C. O. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.06.003 · Cited by 122
Shah, N. J., Al‐Shbool, G., Blackburn, M. J., Cook, M. R., Belouali, A., Liu, S. V., Madhavan, S., He, A. R., Atkins, M. B., Gibney, G. T., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0771-1 · Cited by 121
Park, K., Vansteenkiste, J., Lee, K. H., Pentheroudakis, G., Zhou, C., Prabhash, K., Seto, T., Voon, P. J., Tan, D. S. W., Yang, J. C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.026 · Cited by 122
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Ciciola, P., Cascetta, P., Bianco, C., Formisano, L., & Bianco, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030675 · Cited by 122
ICOS Is an Indicator of T-cell–Mediated Response to Cancer Immunotherapy
Xiao, Z., Mayer, A. T., Nobashi, T. W., & Gambhir, S. S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3265 · Cited by 122
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Botticelli, A., Onesti, C. E., Zizzari, I. G., Cerbelli, B., Sciattella, P., Occhipinti, M. A., Roberto, M., Pietro, F. R. D., Bonifacino, A., Ghidini, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22242 · Cited by 120
Hubbeling, H., Lebow, E. S., Horick, N., Goodwin, K. E., Lin, J. J., Oh, K. S., Shaw, A. T., Mehan, W. A., Shih, H. A., & Gainor, J. F. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.01.012 · Cited by 120
Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer
Wang, H., Agulnik, J. S., Kasymjanova, G., Wang, A., Jiménez, P. P., Cohen, V., Small, D. I., Pepe, C., Sakr, L., Fiset, P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy126 · Cited by 120
PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Velho, P. I., & Antonarakis, E. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1464388 · Cited by 122
Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations
Toki, M. I., Mani, N. L., Smithy, J. W., Liu, Y., Altan, M., Wasserman, B. E., Tuktamyshov, R., Schalper, K. A., Syrigos, K. N., & Rimm, D. L. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.012 · Cited by 120
Linxweiler, M., Kuo, F., Katabi, N., Lee, M., Nadeem, Z., Dalin, M. G., Makarov, V., Chowell, D., Doğan, S., Ganly, I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3758 · Cited by 120
Vijayvergia, N., Dasari, A. N., Deng, M., Litwin, S., Al‐Toubah, T., Alpaugh, R. K., Dotan, E., Hall, M. J., Ross, N., Runyen, M. M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0775-0 · Cited by 120
Impact of high tumor mutational burden in solid tumors and challenges for biomarker application
McNamara, M. G., Jacobs, T., Lamarca, Á., Hubner, R. A., Valle, J. W., & Amir, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102084 · Cited by 120
Skribek, M., Rounis, K., Afshar, S., Grundberg, O., Friesland, S., Tsakonas, G., Ekman, S., & Petris, L. D. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2020.12.012 · Cited by 120
Takasaka, N., Seed, R. I., Cormier, A., Bondesson, A. J., Lou, J., Elattma, A., Ito, S., Yanagisawa, H., Hashimoto, M., Ma, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122591 · Cited by 119
“improved response rates to PD-1 inhibitors compared with tradition chemotherapy (39).”
BackgroundCancer vaccines: Enhanced immunogenic modulation through therapeutic combinations
Gatti-Mays, M. E., Redman, J. M., Collins, J. M., & Bilusic, M. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1364322 · Cited by 116
Pediatric Cancer Immunotherapy: Opportunities and Challenges
Wedekind, M. F., Denton, N. L., Chen, C., & Cripe, T. P. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0297-x · Cited by 121
The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy
Wei, Y., Zhao, Q., Gao, Z., Lao, X.-M., Lin, W.-M., Chen, D.-P., Mu, M., Huang, C.-X., Liu, Z.-Y., Li, B., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127726 · Cited by 111
Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer
Pirker, R. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000592 · Cited by 119
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade
Osorio, J. C., Arbour, K. C., Le, D. T., Durham, J. N., Plodkowski, A. J., Halpenny, D. F., Ginsberg, M. S., Sawan, P., Crompton, J. G., Yu, H. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00709 · Cited by 119
Shah, A. N., Flaum, L., Helenowski, I., Santa-Maria, C. A., Jain, S., RADEMAKER, A. W., Nelson, V. M., Tsarwhas, D., Cristofanilli, M., & Gradishar, W. J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000173 · Cited by 119
Meyo, M. T., Jouinot, A., Leprieur, E. G., Fabre, E., Wislez, M., Alifano, M., Leroy, K., Boudou, P., Tlemsani, C., Khoudour, N., et al. (2020) · Cancers · doi:10.3390/cancers12020473 · Cited by 119
Lin, Z., Huang, L., Li, S., Gu, J., Cui, X., & Zhou, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-78560-3 · Cited by 120
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo
Foggetti, G., Li, C., Cai, H., Hellyer, J. A., Lin, W.-Y., Ayeni, D. O., Hastings, K., Choi, J., Wurtz, A., Andrejka, L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1385 · Cited by 119
Thompson, J. C., Carpenter, E. L., Silva, B. A., Rosenstein, J., Chien, A. L., Quinn, K., Espenschied, C. R., Mak, A. J., Kiedrowski, L. A., Lefterova, M. I., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00321 · Cited by 119
Immunotherapy in non-small cell lung cancer harbouring driver mutations
Addeo, A., Passaro, A., Malapelle, U., Banna, G. L., Subbiah, V., & Friedlaender, A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102179 · Cited by 120
Yin, J., Wu, Y., Yang, X., Gan, L., & Xue, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830631 · Cited by 121
Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis
Sareen, H., Ma, Y., Becker, T. M., Roberts, T. L., SOUZA, P. D., & Powter, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168835 · Cited by 119
Biton, J., Ouakrim, H., Dechartres, A., Alifano, M., Mansuet‐Lupo, A., Si, H., Halpin, R., Creasy, T. H., Bantsimba-Malanda, C., Arrondeau, J., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1110oc · Cited by 119
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
Schmid, S., Diem, S., Li, Q., Krapf, M., Flatz, L., Leschka, S., Desbiolles, L. M., Klingbiel, D., Jochum, W., & Früh, M. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2239-4 · Cited by 118
CRISPR/Cas9 – An evolving biological tool kit for cancer biology and oncology
Tian, X., Gu, T., Patel, S., Bode, A. M., Lee, M., & Dong, Z. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0080-7 · Cited by 119
Vokes, N. I., Liu, D., Ricciuti, B., Jimenez-Aguilar, E., Rizvi, H., Dietlein, F., He, M. X., Margolis, C. A., Elmarakeby, H. A., Girshman, J., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00171 · Cited by 114
Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely
Calles, A., Riess, J. W., & Brahmer, J. R. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280795 · Cited by 118
Self-citationHellmann, M. D., Bivi, N., Calderon, B., Shimizu, T., Delafontaine, B., Liu, Z. T., Szpurka, A. M., Copeland, V., Hodi, F. S., Rottey, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3716 · Cited by 111
Memmott, R. M., Wolfe, A. R., Carbone, D. P., & Williams, T. M. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.017 · Cited by 118
Gettinger, S. N., Redman, M. W., Bazhenova, L. A., Hirsch, F. R., Mack, P. C., Schwartz, L. H., Bradley, J. D., Stinchcombe, T. E., Leighl, N. B., Ramalingam, S. S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2209 · Cited by 118
Karaboué, A., Collon, T., Pavese, I., Bodiguel, V., Cucherousset, J., Zakine, E., Innominato, P. F., Bouchahda, M., Adam, R. A., & Lévi, F. (2022) · Cancers · doi:10.3390/cancers14040896 · Cited by 120
Ellis, P. M., Vella, E. T., & Ung, Y. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.02.001 · Cited by 118
Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
Mittica, G., Ghisoni, E., Giannone, G., Aglietta, M., Genta, S., & Valabrega, G. (2017) · Oncotarget · doi:10.18632/oncotarget.20042 · Cited by 117
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Cadranel, J. L., Canellas, A., Matton, L., Darrason, M., Parrot, A., Naccache, J., Lavolé, A., Ruppert, A.-M., & Fallet, V. (2019) · European Respiratory Review · doi:10.1183/16000617.0058-2019 · Cited by 117
Nakajima, Y., Chamoto, K., Oura, T., & Honjo, T. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103730118 · Cited by 117
Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors
Laenens, D., Yu, Y., Santens, B., Jacobs, J., Beuselinck, B., Bechter, O. E., Wauters, E., Staessen, J. A., Janssens, S. P., & Aelst, L. N. L. V. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01808 · Cited by 117
Yamada, T., Hirai, S., Katayama, Y., Yoshimura, A., Shiotsu, S., Watanabe, S., Kikuchi, T., Hirose, K., Kubota, Y., Chihara, Y., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2037 · Cited by 116
Peters, S., Reck, M., Smit, E. F., Mok, T. S. K., & Hellmann, M. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz109 · Cited by 120
Self-citationLiu, X., Li, M., Wang, X., Dang, Z., Jiang, Y., Wang, X., Kong, Y., & Yang, Z. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02426-5 · Cited by 115
Chen, Y., Pei, Y., Luo, J., Huang, Z., Yu, J., & Meng, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01088 · Cited by 117
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
Gutiontov, S. I., Turchan, W. T., Spurr, L. F., Rouhani, S. J., Chervin, C. S., Steinhardt, G., Lager, A. M., Wanjari, P., Malik, R., Connell, P. P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99524-1 · Cited by 116
Vitale, E., Rizzo, A., Maistrello, L., Güven, D. C., Massafra, R., Mollica, V., Monteiro, F. S. M., Santoni, M., & Massari, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-71746-z · Cited by 117
Recent advancements in lung cancer research: a narrative review
Tang, F. H., Wong, H. Y. T., Tsang, P. S. W., Yau, M., Tam, S. Y., Law, L., Yau, K.-Y., Wong, J., Farah, F. H. M., & Wong, J. (2025) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-979 · Cited by 117
Wang, Q., Yuan, F., Zuo, X., & Li, M. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02505-w · Cited by 121
Aung, T. N., Monkman, J. H., Warrell, J., Vathiotis, I. A., Bates, K., Gavrielatou, N., Trontzas, I. P., Tan, C. W., Fernandez, A. I., Moutafi, M. K., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02351-7 · Cited by 117
Borghaei, H., Langer, C. J., Paz‐Ares, L., Rodríguez‐Abreu, D., Halmos, B., Garassino, M. C., Houghton, B., Kurata, T., Cheng, Y., Lin, J., et al. (2020) · Cancer · doi:10.1002/cncr.33142 · Cited by 115
Self-citationNorum, J., & Nieder, C. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000406 · Cited by 117
Naito, T., Udagawa, H., Umemura, S., Sakai, T., Zenke, Y., Kirita, K., Matsumoto, S., Yoh, K., Niho, S., Tsuboi, M., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.009 · Cited by 115
Takada, K., Sugita, S., Murase, K., Kikuchi, T., Oomori, G., Ito, R., Hayasaka, N., Miyanishi, K., Iyama, S., Ikeda, H., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13215 · Cited by 115
Patient-Centered Palliative Care for Patients With Advanced Lung Cancer
Temel, J. S., Petrillo, L. A., & Greer, J. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01710 · Cited by 116
Michaeli, D. T., & Michaeli, T. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00535 · Cited by 115
Neal, J., Pavlakis, N., Kim, S.-W., Goto, Y., Lim, S. M., Mountzios, G., Fountzilas, E., Mochalova, A., Christoph, D. C., Bearz, A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02166 · Cited by 63
Porrello, A., Leslie, P. L., Harrison, E. B., Gorentla, B. K., Kattula, S., Ghosh, S. K., Azam, S. H., Holtzhausen, A., Chao, Y. L., Hayward, M. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04355-w · Cited by 115
Next generation predictive biomarkers for immune checkpoint inhibition
Khagi, Y., Kurzrock, R., & Patel, S. P. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9652-y · Cited by 115
Radiotherapy and checkpoint inhibitors: a winning new combination?
Ko, E. C., & Formenti, S. C. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918768240 · Cited by 114
Radiologic Pseudoprogression during Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
Katz, S. I., Hammer, M. M., Bagley, S. J., Aggarwal, C., Bauml, J. M., Thompson, J. C., Nachiappan, A. C., Simone, C. B., & Langer, C. J. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.010 · Cited by 114
Jiang, T., Bai, Y., Zhou, F., Li, W., Gao, G., Su, C., Ren, S., Chen, X., & Zhou, C. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.02.009 · Cited by 103
Targeting DNA repair in cancer: current state and novel approaches
Klinakis, A., Karagiannis, D., & Rampias, T. N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03299-8 · Cited by 114
Emancipator, K., Huang, L., Aurora-Garg, D., Bal, T., Cohen, E. E. W., Harrington, K. J., Soulières, D., Tourneau, C. L., Licitra, L. F., Burtness, B. A., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-00710-9 · Cited by 114
Yilmaz, E., Ismaila, N., Bauman, J. E., Dabney, R. S., Gan, G. N., Jordan, R. C., Kaufman, M., Kirtane, K., McBride, S. M., Old, M. O., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.02328 · Cited by 115
Liu, W., You, W., Lan, Z., Ren, Y., Gao, S., Li, S., Chen, W., Huang, C., Zeng, Y., Xiao, N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101448 · Cited by 115
Hanna, N. H., Johnson, D. H., Temin, S., & Masters, G. A. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.026716 · Cited by 113
Goldstein, D. A., Gordon, N., Davidescu, M., Leshno, M., Steuer, C. E., Patel, N. T., Stemmer, S. M., & Zer, A. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx063 · Cited by 113
Ilié, M., Khambata‐Ford, S., Copie‐Bergman, C., Huang, L., Juco, J. W., Hofman, V., & Hofman, P. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183023 · Cited by 113
Oya, Y., Yoshida, T., Kuroda, H., Mikubo, M., Kondo, C., Shimizu, J., Horio, Y., Sakao, Y., Hida, T., & Yatabe, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.21602 · Cited by 115
Management of co-existent tuberculosis and lung cancer
Ho, J., & Leung, C. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.05.030 · Cited by 113
Hou, Y., Chao, Y., Hsieh, M.-H., Tung, H., Wang, H., & Shan, Y. (2019) · Cancers · doi:10.3390/cancers11040541 · Cited by 113
Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost
Kuo, C.-N., Liao, Y., Kuo, L., Tsai, H., Chang, W., & Yen, Y. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.08.023 · Cited by 113
Kraman, M., Faroudi, M., Allen, N. L., Kmiecik, K., Gliddon, D., Seal, C. J., Koers, A., Wydro, M. M., Batey, S., Winnewisser, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3548 · Cited by 115
Adjuvant and Neoadjuvant Immunotherapy in Non–small Cell Lung Cancer
Broderick, S. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.001 · Cited by 113
Metadata
- Authors
- Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leiby, M. A., Lubiniecki, G. M., Shentu, Y., Rangwala, R., & Brahmer, J. R.
- Affiliations
- The University of Sydney (AU)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-10
- Volume
- 375
- Issue
- 19
- Pages
- 1823-1833
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2527905628
- Cited by
- 10,089
- References
- 54
- Citations by year
- 2026: 584 · 2025: 750 · 2024: 913 · 2023: 1012 · 2022: 1108 · 2021: 1321 · 2020: 1324 · 2019: 1154 · 2018: 1132 · 2017: 724 · 2016: 46
- FWCI
- 548.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- pembrolizumab, PD-L1-positive non-small cell lung cancer, PD-1 inhibitors, immune checkpoint inhibitors, platinum-based chemotherapy, progression-free survival, overall survival, objective response rate, treatment-related adverse events, EGFR wild-type, immunotherapy versus chemotherapy, duration of response
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Platinum Compounds, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.